By Robert M. DiSogra

Audiologists have known about the ototoxicity of quinine (and its derivatives) and antibiotics (macrolide and aminoglycoside) for decades. But we have never seen the combined use of two drugs, each with known ototoxic potential, being used as an intervention strategy for the coronavirus pandemic (COVID-19).

In an effort to combat the coronavirus (COVID-19), front-line physicians are repurposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19.

At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients.

Read the full article online.

Share this

Related Posts

Admission Rates of Neonatal Intensive Care Units in the United States

A New Flexible Auditory Brainstem Implant

Prevalence of Depression in Teenagers and Adults in the United States

Recent Posts

Admission Rates of Neonatal Intensive Care Units in the United States

Pediatric audiology case-history questionnaires often ask about birth history and time spent in a neonatal intensive care unit (NICU). As such, audiologists who routinely see…

Read More

A New Flexible Auditory Brainstem Implant

An auditory brainstem implant (ABI) provides the sensation of sound to individuals who are deaf due to neurofibromatosis 2 (NF2) or a severely compromised or…

Read More

Nevada Passes Bill to Join ASLP-IC as Legislative Session Closes

On the final day of the Nevada Legislative Session, lawmakers passed Assembly Bill (AB) 230, which was then sent to Governor Joe Lombardo for signature….

Read More